royalty rates from bell potter for docetaxel and cabaziraxel seem to high and not Aligned with normal rates for drug delivery agents of generic drugs. Those rates are more for new drugs. Maybe argue could apply to dep- sn38 but highwr risk with unapproved drug like sn-38 and needs more supporting data for approval - for safe and effective- Even though it’s is metabolites and bypass liver metabolism.
sales will determine by how much safer and better than existing drug and so far we not have strong evidence just a few case studies and some interim promising data without stats.
- Forums
- ASX - By Stock
- DEP the path to money?
royalty rates from bell potter for docetaxel and cabaziraxel...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.5¢ |
Change
-0.003(3.06%) |
Mkt cap ! $39.17M |
Open | High | Low | Value | Volume |
10.0¢ | 10.0¢ | 9.5¢ | $12.55K | 130.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 586785 | 9.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.7¢ | 56840 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 586785 | 0.095 |
2 | 10000 | 0.094 |
1 | 28393 | 0.093 |
1 | 50000 | 0.092 |
2 | 16000 | 0.090 |
Price($) | Vol. | No. |
---|---|---|
0.097 | 56840 | 1 |
0.100 | 8705 | 2 |
0.105 | 96531 | 4 |
0.110 | 39609 | 6 |
0.115 | 138531 | 6 |
Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online